GLP-1 Advisor | One Day MD

By Dr. Frank Yap, MD, One Day Media Network · Published 2026-10-04 · Last updated 2026-10-04 · Reading time about 12 minutes Quick Answer Ozempic and Wegovy are the same drug (semaglutide); Mounjaro and Zepbound are the same drug (tirzepatide). Ozempic and Mounjaro are labeled for type 2 diabetes, while Wegovy and Zepbound are labeled for weight management. In the head-to-head SURMOUNT-5 trial, tirzepatide produced 20.2% weight loss versus 13.7% for semaglutide at 72 weeks. The right choice depends on diagnosis, coverage, tolerability and other conditions. In this article Are these four drugs different or the same? Side-by-side comparison table Which produces more weight loss? Heart, kidney, liver and sleep apnea indications Side effects and who should avoid the...

Updated: October 3, 2026  |  Evidence review: Human clinical trials, systematic reviews, regulatory labeling and longevity research Can Ozempic, Wegovy, Mounjaro or Zepbound slow aging? GLP-1-based medicines have moved far beyond the original weight-loss conversation. Large clinical trials have shown meaningful benefits for cardiovascular outcomes, kidney disease, obesity-related heart failure and obstructive sleep apnea. Those effects could translate into healthier aging for appropriately selected patients. But that is not the same as proving that GLP-1 drugs directly slow the biological aging process or extend the maximum human lifespan. As of 2026, that distinction remains critical. OneDayMD evidence position: GLP-1 medicines should currently be viewed primarily as treatments for obesity, type 2 diabetes and selected obesity-related diseases—not as established anti-aging or lifespan-extension drugs. The strongest longevity ...